Stifel Reiterates Biogen (BIIB) at Buy with $299 PT Following CEO Appointment
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterates Biogen (NASDAQ: BIIB) at Buy with a price target of $299.00, following the company appointment ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
